Latest Muscarinic antagonists Stories
RIDGEFIELD, Conn., Nov. 3, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S.
Data for the co-administration of Spiriva® HandiHaler® (tiotropium bromide inhalation powder) + Striverdi® Respimat® (olodaterol) Inhalation Spray presented at CHEST 2014 RIDGEFIELD,
Approval Marks New Inhaler Choice for tiotropium RIDGEFIELD, Conn., Sept. 25, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S.
GENEVA, September 15, 2014 /PRNewswire/ -- Following the decision by the principal European manufacturers to exit or end market development and regulatory support for the
Additionally, data from the WISDOM trial on stepwise withdrawal of ICS in COPD was also presented at ERS and simultaneously published in the New England Journal of Medicine RIDGEFIELD,
For U.S. Media Only RIDGEFIELD, Conn., Sept.
For U.S. Media Only RIDGEFIELD, Conn., Aug. 19, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S.
Committee Voted Based on Clinical Data from Eight Efficacy Trials RIDGEFIELD, Conn., Aug. 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
- First results of the pivotal Phase 3 INPULSIS(TM) trials investigating the efficacy and safety of nintedanib, an investigational compound, in the treatment of idiopathic pulmonary fibrosis (IPF)
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.